XML 15 R10.htm IDEA: XBRL DOCUMENT
v2.4.0.8

License Agreements | 9 Months Ended
--- | ---
Aug. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract] |
License Agreements | Note 5 - License Agreements The Company has entered into license agreements with certain investors in various international markets in an attempt to capitalize on the Company’s technology. The investors typically pay a licensing fee to receive Company marketing programs, technology and know-how in a selected area. The licensing agreement may also give the investor the right to sell sub-license agreements. As part of the accounting for the up-front license revenue, revenue from the up-front license fee is recognized based on such factors as when the payment is due, collectability and when all material services or conditions relating to the sale have been substantially performed based on the terms of the agreement. The Company enters into two types of licensing agreements and in both types, the Company earns revenue on the initial license fees. Under the technology agreements, the Company earns processing and storage royalties from the affiliates that process in their own facility. Under the marketing agreements, the Company earns processing and storage revenues from affiliates that store specimens in the Company’s facility in Oldsmar, Florida. Technology Agreements The Company has entered into definitive License and Royalty Agreements with Cryo-Cell de Mexico (“Mexico”) and Asia Cryo-Cell Private Limited to establish and market its umbilical cord blood program in Mexico and India, respectively. The Company has entered into definitive License and Royalty Agreements with Asia Cryo-Cell Private Limited and S-Evans Bio-Sciences, Inc. to establish and market its menstrual stem cell program in India and China, respectively. On August 19, 2011, the Company received notification from Mexico that it was terminating the license agreement effective immediately due to an alleged breach of the license agreement. On October 17, 2011, the Company and Mexico entered into an amendment to the license agreement whereby the termination has been revoked and Mexico will pay the Company $1,863,000 in 37 monthly installments of $50,000 beginning on October 17, 2011 with a final payment of $13,000 on November 15, 2014. Mexico will have no other continuing obligations to the Company for royalties or other license payments and the agreement will be effectively terminated once the entire $1,863,000 has been received. Mexico also has the option to pay the full amount early with no penalties. Upon termination of this agreement, the Company expects a reduction of licensee income in future periods. As of August 31, 2013 and November 30, 2012, the Company recorded a receivable from Mexico of $694,238 and $1,115,505, respectively, and deferred revenue of $692,120 and $1,104,623, respectively, in the accompanying consolidated balance sheets. The receivable is calculated using the present value of all of the monthly installments using a discount rate that reflects both the risk-free rate at the inception of the contract and the contract period. In accordance with the agreement, the Company received nine installments of $50,000 during the nine months ended August 31, 2013 and August 31, 2012, which is reflected in the consolidated statement of operations as of August 31, 2013 and August 31, 2012 as licensee and other income. The installment amounts that are to be received and recognized within the next twelve months have been classified as short-term as Accounts Receivable in the accompanying consolidated balance sheets. Marketing Agreements The Company has definitive license agreements to market both the Company’s umbilical cord blood and menstrual stem cell programs in Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama and Pakistan. In October 2012, the Company sent notice of termination to the Company’s Venezuelan affiliate, which represents Venezuela, Chile, Colombia and Peru, for failure to meet its payment obligation in accordance with the contract. Subsequent to the notice of termination, payment was received for outstanding processing and storage fees due from Venezuela. The Company is in the process of discussing a new agreement. The Company continues to accept umbilical cord blood stem cell specimens to be processed and stored during the negotiations. In December 2012, the Company sent notice of termination to the Company’s affiliate in Ecuador for failure to meet its payment obligation in accordance with the contract. Subsequent to the notice of termination, payment was received for outstanding processing and storage fees due from Ecuador. In August 2013, the Company was notified that its affiliate in Ecuador was temporarily closed by the National Institute of Organic Donation (INDOT). As a result, the Company recorded an allowance for uncollectible receivables for the $150,000 processing and storage receivable due from Ecuador in the third quarter of fiscal 2013. Processing and storage revenues from specimens originating in foreign territories that store at the Company’s facility in Oldsmar, Florida totaled approximately $381,000 and $392,000 for the three months ended August 31, 2013 and August 31, 2012, respectively, and are reflected in processing and storage fees in the accompanying consolidated statements of operations. Processing and storage revenues from specimens originating in foreign territories that store at the Company’s facility in Oldsmar, Florida totaled approximately $1,134,000 and $1,185,000 for the nine months ended August 31, 2013 and August, 31, 2012, respectively, and are reflected in processing and storage fees in the accompanying consolidated statements of operations. The following table details the initial license fees for the technology and marketing agreements and processing and storage royalties earned under the technology agreements for the three and nine months ended August 31, 2013 and August 31, 2012. The initial license fees and processing and storage royalties are reflected in licensee income in the accompanying consolidated statements of operations.
|  | Three Months Ended August 31, 2013 |  |  | Nine Months Ended August 31, 2013 |
|  | License Fee |  |  | Process and Storage Royalties |  |  | Total |  |  | License Fee |  |  | Process and Storage Royalties |  |  | Total |
India |  | $ | — |  |  | $ | 169,411 |  |  | $ | 169,411 |  |  | $ | — |  |  | $ | 508,235 |  |  | $ | 508,235 |
Mexico |  |  | — |  |  |  | 154,405 |  |  |  | 154,405 |  |  |  | — |  |  |  | 467,345 |  |  |  | 467,345 |
Total |  | $ |  |  |  | $ | 323,816 |  |  | $ | 323,816 |  |  | $ |  |  |  | $ | 975,580 |  |  | $ | 975,580 |
|  | Three Months Ended August 31, 2012 |  |  | Nine Months Ended August 31, 2012 |
|  | License Fee |  |  | Process and Storage Royalties |  |  | Total |  |  | License Fee |  |  | Process and Storage Royalties |  |  | Total |
India |  | $ | — |  |  | $ | 169,412 |  |  | $ | 169,412 |  |  | $ | — |  |  |  | 508,235 |  |  |  | 508,235 |
Mexico |  |  | — |  |  |  | 156,969 |  |  |  | 156,969 |  |  |  | — |  |  |  | 464,021 |  |  |  | 464,021 |
Costa Rica |  |  | 25,000 |  |  |  |  |  |  |  | 25,000 |  |  |  | 25,000 |  |  |  |  |  |  |  | 25,000 |
Nicaragua |  |  | 5,000 |  |  |  | — |  |  |  | 5,000 |  |  |  | 20,000 |  |  |  | — |  |  |  | 20,000 |
Total |  | $ | 30,000 |  |  | $ | 326,381 |  |  | $ | 356,381 |  |  | $ | 45,000 |  |  | $ | 972,256 |  |  | $ | 1,017,256 |

X
- Definition The entire disclosure for license agreements. + References No definition available. + Details
Name: | ccel_LicenseAgreementsTextBlock
Namespace Prefix: | ccel_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration